{Reference Type}: Case Reports
{Title}: Reactive cutaneous capillary endothelial proliferations of the eyelids induced by camrelizumab: A case report.
{Author}: Zhou X;Yan X;Wu Y;
{Journal}: Biomed Rep
{Volume}: 20
{Issue}: 3
{Year}: 2024 Mar
暂无{DOI}: 10.3892/br.2024.1743
{Abstract}: With the widespread application of immune checkpoint inhibitors, a series of adverse events (AEs) related to treatment resulting from alterations in the immune system have emerged that warrant attention. The present study report the case of a patient with reactive cutaneous capillary endothelial proliferations (RCCEPs) on the eye lid, following treatment with the programmed cell death protein 1 inhibitor camrelizumab (SHR-1210) for stage IIa2 well- to moderately differentiated squamous cell carcinoma of the cervix. Although RCCEPs have been revealed to be the most common AEs of SHR-1210, they are usually distributed on the head, neck, trunk and extremities. The current study presents a rare case of ocular RCCEPs induced by SHR-1210. Prompt diagnosis and treatment of immune-related AEs is crucial for the optimal management of patients. Although RCCEPs are usually slight-risk toxicities that pose no threat to the continuity of treatment, lesions with unusual distributions that cause disturbances in normal life require proper treatment, such as surgical excision.